Status:
COMPLETED
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Non-Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study will assess the efficacy and safety of Avastin combined with first li ne paclitaxel-carboplatin (cohort 1) or second line Tarceva (cohort 2) in patien ts with non-squamous non-small cell lu...
Eligibility Criteria
Inclusion
- adult patients, \>=18 years of age;
- stage IV non-squamous non-small cell lung cancer;
- asymptomatic, untreated brain metastasis;
- ECOG performance status 0-1.
Exclusion
- previous treatment for brain metastasis;
- history of migraine or epilepsy;
- previous treatment with angiogenesis inhibitors;
- for cohort 2, previous first line treatment with Avastin or Tarceva;
- current or recent use of aspirin (\>325mg/day) or full-dose anticoagulants or thrombolytic agent for therapeutic purposes.
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2012
Estimated Enrollment :
91 Patients enrolled
Trial Details
Trial ID
NCT00800202
Start Date
April 1 2009
End Date
October 1 2012
Last Update
November 19 2014
Active Locations (25)
Enter a location and click search to find clinical trials sorted by distance.
1
Bordeaux, France, 33076
2
Brest, France, 29200
3
Caen, France, 14076
4
Chartres, France, 28018